These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 25248688

  • 1. Underestimation of unfractionated heparin therapy assessment due to platelet activation when using partial-draw (pediatric) citrate collection tubes.
    Desconclois C, Eschwège V, Proulle V, Boutekedjiret T, Dreyfus M, Toulon P.
    Thromb Res; 2014 Nov; 134(5):1117-22. PubMed ID: 25248688
    [Abstract] [Full Text] [Related]

  • 2. A new plastic collection tube made of polyethylene terephtalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractionated heparin, and low molecular weight heparin).
    Toulon P, Ajzenberg N, Smahi M, Guillin MC.
    Thromb Res; 2007 Nov; 119(2):135-43. PubMed ID: 16426667
    [Abstract] [Full Text] [Related]

  • 3. [Theophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?].
    Billoir P, Clavier T, Guilbert A, Barbay V, Chrétien MH, Fresel M, Abriou C, Girault C, Le Cam Duchez V.
    Ann Biol Clin (Paris); 2020 Feb 01; 78(1):27-34. PubMed ID: 32108577
    [Abstract] [Full Text] [Related]

  • 4. A low volume specimen container suitable for monitoring the aPTT of heparinized patients.
    Ray MJ, Carroll PA, Just SJ, Hawson GA.
    Blood Coagul Fibrinolysis; 1993 Oct 01; 4(5):805-7. PubMed ID: 8292732
    [Abstract] [Full Text] [Related]

  • 5. Monitoring treatments with unfractionated heparin: CTAD must be used instead of citrate as the anticoagulant solution when using partial-draw collection tubes. Results of a multicenter evaluation.
    Toulon P, Abecassis L, Smahi M, Ternisien C.
    Thromb Res; 2010 Dec 01; 126(6):536-42. PubMed ID: 20950840
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Is citrate theophylline adenosine dipyridamole (CTAD) better than citrate to survey unfractionated heparin treatment? Has delayed centrifugation a real impact on this survey?
    Billoir P, Clavier T, Guilbert A, Barbay V, Chrétien MH, Fresel M, Abriou C, Girault C, Le Cam Duchez V.
    J Thromb Thrombolysis; 2019 Aug 01; 48(2):277-283. PubMed ID: 31098816
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS.
    Ann Pharmacother; 2011 Jul 01; 45(7-8):861-8. PubMed ID: 21712506
    [Abstract] [Full Text] [Related]

  • 12. [The study of anticoagulants selection in platelet-rich plasma preparation].
    Hua L, Lai G, Zhenjun L, Guie M.
    Zhonghua Zheng Xing Wai Ke Za Zhi; 2015 Jul 01; 31(4):295-300. PubMed ID: 26665933
    [Abstract] [Full Text] [Related]

  • 13. Assessment of platelet activation in several different anticoagulants by the Advia 120 Hematology System, fluorescence flow cytometry, and electron microscopy.
    Ahnadi CE, Sabrinah Chapman E, Lépine M, Okrongly D, Pujol-Moix N, Hernández A, Boughrassa F, Grant AM.
    Thromb Haemost; 2003 Nov 01; 90(5):940-8. PubMed ID: 14597991
    [Abstract] [Full Text] [Related]

  • 14. Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.
    van den Besselaar AM, Meeuwisse-Braun J, Jansen-Grüter R, Bertina RM.
    Thromb Haemost; 1987 Apr 07; 57(2):226-31. PubMed ID: 3603414
    [Abstract] [Full Text] [Related]

  • 15. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A, Alban S, Omer-Adam MA, Weitschies W, Warkentin TE.
    Thromb Res; 2008 Apr 07; 122(2):211-20. PubMed ID: 18262226
    [Abstract] [Full Text] [Related]

  • 16. Monitoring heparin therapy: APTT results from partial- vs full-draw tubes.
    Siegel JE, Bernard DW, Swami VK, Sazama K.
    Am J Clin Pathol; 1998 Aug 07; 110(2):184-7. PubMed ID: 9704617
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time.
    Heyns AD, van den Berg DJ, Kleynhans PH, du Toit PW.
    J Clin Pathol; 1981 Jan 07; 34(1):63-8. PubMed ID: 7462439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.